EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

India Globalization Capital Inc (IGC) fair value: what the stock is really worth

We calculate from audited financials what India Globalization Capital Inc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jun 24, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US45408X3089

IG India Globalization Capital Inc logo Thin data Jun 24, 2026

India Globalization Capital Inc

IGC · US

Weak valuationQuality is weak on top of the rich price.

!Fair value $0.2380 · Overvalued (−17%)
!Quality 24/100
!Weak Growth (revenue 5y −20.8 %/yr)
!Low debt · negative free cash flow
!Trails peers (2/8)
!Narrow moat 3/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 11 out of 100
Watch India Globalization Capital Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$2.80 $0.2400 Fair Value $0.2380 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 24, 2026.

How to read this chart

60‑month range $0.2400 – $2.80 · fair‑value band $0.1785 – $0.3060 · the $0.2861 price screens above the $0.2380 fair value. Dashed = 300-day average. As of Jun 24, 2026.

Follow India Globalization Capital in your weekly email

Every Wednesday you see whether India Globalization Capital is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia.

Show more

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.

Stock analysis

India Globalization Capital Inc (IGC) currently trades at $0.2861, while our model-based Fair Value estimate is $0.2380, implying the stock looks roughly 20.2% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.1785 (bear) to $0.3060 (bull), the price of $0.2861 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

India Globalization Capital Inc reported revenue of $1.3M in FY2025 versus $898K in FY2021, a compound +9.1%/yr. Reported net income was −$7.1M in FY2025.

Key figures

Market cap $27.5M · P/S ratio 24.9 · EPS (TTM) $−0.0600 · Return on equity −83.3% · Return on assets (EBIT) −66.7% · Operating margin −775% · Revenue (TTM) $1.1M · Revenue growth (YoY) −3.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 32% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −17%, IGC screens richer than that median.

Fair Value models

Bear $0.1785 Fair Value $0.2380 Bull $0.3060
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.0300 $0.0400 $0.0600 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.0300 $0.0400 $0.0600 54

Open the full fair value analysis →

Notify me when IGC reaches fair value

Put IGC on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 24/100

Of which business quality 27 · Market factors (momentum, volatility) 38

Profitability 3
Margins and returns on capital today
Quality Growth 51
Are margins and returns improving?
Cashflow 4
Earnings quality: real cash, not paper profit
Fin. Strength 54
Balance sheet, leverage, solvency risk
Investment 67
Disciplined investing over empire-building
Low Volatility 57
Calm price path (market factor)
Momentum 40
Price trend over the last 3–12 months (market factor)
52W Momentum 14
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−5.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+47.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−20.8%
Start year 2020 (pandemic). Over 10 years: −16.5% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−168.6% (2020) → −585.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

IGC screens 20% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare India Globalization Capital Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside −17% · Above median
Profitability
Return on assets −50% · Bottom 25%
Growth and dividend
Revenue growth −4% · Below median
Balance sheet
Debt / equity 0.02× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.35× · Priciest 25%
P/S (TTM) 24.88× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)11 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)99 · sector 97
DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $516.34 $567.97 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

India Globalization Capital Inc · Fair Value
$0.2380 −20%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "India Globalization Capital Inc Fair Value". https://www.fairvalue-calculator.com/stock/IGC

Frequently asked questions

Is India Globalization Capital Inc (IGC) overvalued or undervalued?
As of Jun 24, 2026, our model estimates a fair value of $0.2380 versus a price of $0.2861, about −17% upside (overvalued).
What is the fair value of IGC?
Our model-based fair value for India Globalization Capital Inc is $0.2380 (as of Jun 24, 2026), built from audited fundamentals. The current price: $0.2861.
What is the quality score of IGC?
India Globalization Capital Inc has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for India Globalization Capital Inc (IGC)?
Our model-based price target is the fair value of $0.2380 (as of Jun 24, 2026) from 1 valuation models. Cautious scenario $0.1785, optimistic scenario $0.3060. It is a calculation from audited fundamentals, not an analyst target.
What is the India Globalization Capital Inc stock forecast for 2026?
Our models put fair value at $0.2380, about −17% upside versus a price of $0.2861 (overvalued). Cautious scenario $0.1785, optimistic scenario $0.3060. The calculation is refreshed regularly with new filings.
What is the revenue of India Globalization Capital Inc (IGC)?
India Globalization Capital Inc reported trailing-twelve-month revenue of about $1.1M (latest available figure, as of Jun 24, 2026).
What is the intrinsic value of India Globalization Capital Inc (IGC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For India Globalization Capital Inc it is $0.2380 per share (as of Jun 24, 2026), against a price of $0.2861. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is India Globalization Capital Inc stock overvalued or undervalued in 2026?
As of Jun 24, 2026, IGC trades above its calculated fair value: price $0.2861, fair value $0.2380, a gap of about −17% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IGC?
No. The price is what the market pays today ($0.2861); the fair value is what the company's own numbers justify ($0.2380). For India Globalization Capital Inc the two are $0.0481 per share apart. That gap is exactly why we show both numbers side by side.
How much is India Globalization Capital Inc worth?
The market values India Globalization Capital Inc at about $27.5M (market capitalisation, as of Jun 24, 2026). Per share that is $0.2861; our models calculate a fair value of $0.2380 per share.
What do the bullish and bearish scenarios say about IGC?
Our models span a range for India Globalization Capital Inc: cautious scenario $0.1785, base $0.2380, optimistic $0.3060 per share (as of Jun 24, 2026, price $0.2861). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of India Globalization Capital Inc (IGC)?
Balance-sheet figures for India Globalization Capital Inc (as of Jun 24, 2026): return on equity −83.3%, debt of 0.02 per unit of equity. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is IGC from its 52-week high?
India Globalization Capital Inc trades at $0.2861, about 32% below its 52-week high of $0.4200 and 19% above the low of $0.2400 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2380 is for.
Which stocks are comparable to India Globalization Capital Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is India Globalization Capital Inc stock attractive at the current price?
The data as of Jun 24, 2026: price $0.2861, calculated fair value $0.2380 (−17%), Quality Score 24/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IGC calculated?
We run India Globalization Capital Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.2380, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. India Globalization Capital Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of India Globalization Capital Inc (IGC)?
The closing price on Sep 23, 2026 was $0.2861. Our model-based fair value is $0.2380, about −17% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with India Globalization Capital Inc right now?
Weak quality (24/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of India Globalization Capital Inc

How large is the market capitalisation of India Globalization Capital Inc (IGC)?
The market capitalisation of India Globalization Capital Inc is $27.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of India Globalization Capital Inc (IGC)?
The price-to-sales ratio of India Globalization Capital Inc is 24.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of India Globalization Capital Inc (IGC)?
Earnings per share at India Globalization Capital Inc are $−0.0600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of India Globalization Capital Inc (IGC)?
The return on equity (ROE) of India Globalization Capital Inc is −83.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of India Globalization Capital Inc (IGC)?
On an EBIT basis the return on assets of India Globalization Capital Inc is −66.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of India Globalization Capital Inc (IGC)?
The operating margin of India Globalization Capital Inc is −775% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at India Globalization Capital Inc (IGC)?
Revenue at India Globalization Capital Inc is growing −3.9% versus a year earlier (3y avg +47.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does India Globalization Capital Inc (IGC) generate?
The free cash flow of India Globalization Capital Inc is −$5.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does India Globalization Capital Inc (IGC) hold?
India Globalization Capital Inc holds more cash than debt, $167K net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch India Globalization Capital Inc in the live analysis

One click puts India Globalization Capital Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.